{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:55:09Z","timestamp":1789692909465,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An mRNA-based respiratory syncytial virus (RSV) vaccine, mRNA-1345, is under clinical investigation to address RSV disease burden in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on a randomized, observer-blind, placebo-controlled design, this phase 1 dose-ranging study evaluated the safety, reactogenicity, and immunogenicity of mRNA-1345 in adults aged 65 to 79 years. Participants were randomized to receive 1 dose of mRNA-1345 (12.5, 25, 50, 100, or 200 \u00b5g) or placebo and matched mRNA-1345 booster or placebo at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 298 participants received the first injection and 247 received the 12-month booster injection. mRNA-1345 was generally well tolerated after both injections, with the most frequently reported solicited adverse reactions being injection site pain, fatigue, headache, arthralgia, and myalgia. Reactogenicity was higher after the booster injection but with severity, time to onset, and duration similar to the first injection. A single mRNA-1345 injection boosted RSV-A and RSV-B neutralizing antibody titers and prefusion F binding antibody (preF bAb) concentrations at 1 month (geometric mean fold rises: RSV-A, 10.2\u201316.5; RSV-B, 5.3\u201312.5; preF bAb, 7.2\u201312.1). RSV antibody levels remained above baseline through 12 months, indicating immune persistence. A 12-month booster injection also increased RSV-A and RSV-B neutralizing antibody titers and preF bAb concentrations; titers after booster injection were numerically lower than those after the first dose, with overlapping 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>mRNA-1345 was well tolerated and immunogenic following a single injection and a 12-month booster.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT04528719 (ClinicalTrials.gov).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae081","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T17:17:50Z","timestamp":1708449470000},"page":"e647-e656","source":"Crossref","is-referenced-by-count":59,"title":["Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults"],"prefix":"10.1093","volume":"230","author":[{"given":"Christine A","family":"Shaw","sequence":"first","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Essink","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research , Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Harper","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research , Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runa","family":"Mithani","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Dhar","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wilson","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A","family":"Panozzo","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Wilson","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana K","family":"Simorellis","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reuter","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia K","family":"Stoszek","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L","family":"Chen","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Goswami","sequence":"additional","affiliation":[{"name":"Infectious Disease, Research and Development, Moderna, Inc , Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"2024092316153519300_jiae081-B1","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1016\/S2214-109X(19)30264-5","article-title":"Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis","volume":"7","author":"Li","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2024092316153519300_jiae081-B2","author":"Centers for Disease Control and Prevention"},{"key":"2024092316153519300_jiae081-B3","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global disease burden estimates of respiratory syncytial virus\u2013associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J Infect Dis"},{"key":"2024092316153519300_jiae081-B4","author":"Centers for Disease Control and Prevention"},{"key":"2024092316153519300_jiae081-B5","author":"Centers for Disease Control and Prevention"},{"key":"2024092316153519300_jiae081-B6","author":"Mayo Clinic"},{"key":"2024092316153519300_jiae081-B7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/CMR.00010-16","article-title":"Respiratory syncytial virus: infection, detection, and new options for prevention and treatment","volume":"30","author":"Griffiths","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2024092316153519300_jiae081-B8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","article-title":"Respiratory syncytial virus infection","volume":"354","author":"Simoes","year":"1999","journal-title":"Lancet"},{"key":"2024092316153519300_jiae081-B9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/jmv.20090","article-title":"Age related differences in humoral immune response to respiratory syncytial virus infection in adults","volume":"73","author":"Walsh","year":"2004","journal-title":"J Med Virol"},{"key":"2024092316153519300_jiae081-B10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/jmv.20724","article-title":"Serum antibody decay in adults following natural respiratory syncytial virus infection","volume":"78","author":"Falsey","year":"2006","journal-title":"J Med Virol"},{"key":"2024092316153519300_jiae081-B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/eri.10.140","article-title":"Respiratory syncytial virus disease: update on treatment and prevention","volume":"9","author":"Krilov","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024092316153519300_jiae081-B12","author":"Norton Healthcare"},{"key":"2024092316153519300_jiae081-B13","author":"World Health Organization"},{"key":"2024092316153519300_jiae081-B14","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"2024092316153519300_jiae081-B15","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40121-023-00802-4","article-title":"Incidence of respiratory syncytial virus infection in older adults: limitations of current data","volume":"12","author":"Rozenbaum","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2024092316153519300_jiae081-B16","author":"National Foundation for Infectious Diseases"},{"key":"2024092316153519300_jiae081-B17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2024092316153519300_jiae081-B18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"2024092316153519300_jiae081-B19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"2024092316153519300_jiae081-B20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-based vaccine antigen design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu Rev Med"},{"key":"2024092316153519300_jiae081-B21","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F\u2013specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci Transl Med"},{"key":"2024092316153519300_jiae081-B22","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3389\/fimmu.2019.01006","article-title":"Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade","volume":"10","author":"Aranda","year":"2019","journal-title":"Front Immunol"},{"key":"2024092316153519300_jiae081-B23","author":"United States Food and Drug Administration"},{"key":"2024092316153519300_jiae081-B24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"key":"2024092316153519300_jiae081-B25","author":"European Medicines Agency"},{"key":"2024092316153519300_jiae081-B26","author":"Pfizer"},{"key":"2024092316153519300_jiae081-B27","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"2024092316153519300_jiae081-B28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2024092316153519300_jiae081-B29","doi-asserted-by":"crossref","first-page":"100746","DOI":"10.1016\/j.eclinm.2021.100746","article-title":"mRNA vaccines: a matter of delivery","volume":"32","author":"Cao","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024092316153519300_jiae081-B30","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"2024092316153519300_jiae081-B31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2024092316153519300_jiae081-B32","author":"Pfizer"},{"key":"2024092316153519300_jiae081-B33","author":"Vaccines and Related Biological Products Advisory Committee"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae081\/56949603\/jiae081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/3\/e647\/59248505\/jiae081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/3\/e647\/59248505\/jiae081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T12:15:52Z","timestamp":1727093752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/3\/e647\/7612559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae081","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,15]]},"published":{"date-parts":[[2024,2,22]]}}}